Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash from Investing Activities (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Cash from Investing Activities data on record, last reported at -$242000.0 in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 157.45% year-over-year to -$242000.0; the TTM value through Oct 2025 reached -$583000.0, down 218.58%, while the annual FY2025 figure was -$389000.0, 53.47% up from the prior year.
  • Cash from Investing Activities reached -$242000.0 in Q4 2025 per CSBR's latest filing, down from -$46000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $3000.0 in Q2 2024 and bottomed at -$1.2 million in Q1 2021.
  • Average Cash from Investing Activities over 5 years is -$463473.7, with a median of -$506000.0 recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: soared 100.39% in 2024, then plummeted 8533.33% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$566000.0 in 2021, then fell by 6.71% to -$604000.0 in 2022, then surged by 86.92% to -$79000.0 in 2023, then decreased by 18.99% to -$94000.0 in 2024, then tumbled by 157.45% to -$242000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$242000.0 in Q4 2025, -$46000.0 in Q3 2025, and -$253000.0 in Q2 2025.